Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful in...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308181/ https://www.ncbi.nlm.nih.gov/pubmed/37396553 http://dx.doi.org/10.1016/j.gendis.2022.07.023 |
_version_ | 1785066192119005184 |
---|---|
author | Padinharayil, Hafiza Varghese, Jinsu John, Mithun Chacko Rajanikant, Golgodu Krishnamurthy Wilson, Cornelia M. Al-Yozbaki, Minnatallah Renu, Kaviyarasi Dewanjee, Saikat Sanyal, Rupa Dey, Abhijit Mukherjee, Anirban Goutam Wanjari, Uddesh Ramesh Gopalakrishnan, Abilash Valsala George, Alex |
author_facet | Padinharayil, Hafiza Varghese, Jinsu John, Mithun Chacko Rajanikant, Golgodu Krishnamurthy Wilson, Cornelia M. Al-Yozbaki, Minnatallah Renu, Kaviyarasi Dewanjee, Saikat Sanyal, Rupa Dey, Abhijit Mukherjee, Anirban Goutam Wanjari, Uddesh Ramesh Gopalakrishnan, Abilash Valsala George, Alex |
author_sort | Padinharayil, Hafiza |
collection | PubMed |
description | Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance. |
format | Online Article Text |
id | pubmed-10308181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Chongqing Medical University |
record_format | MEDLINE/PubMed |
spelling | pubmed-103081812023-06-30 Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics Padinharayil, Hafiza Varghese, Jinsu John, Mithun Chacko Rajanikant, Golgodu Krishnamurthy Wilson, Cornelia M. Al-Yozbaki, Minnatallah Renu, Kaviyarasi Dewanjee, Saikat Sanyal, Rupa Dey, Abhijit Mukherjee, Anirban Goutam Wanjari, Uddesh Ramesh Gopalakrishnan, Abilash Valsala George, Alex Genes Dis Review Article Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information for cancer prevention, diagnosis, and management, supporting health-care interventions. Global cancer mortality projections from 2016 to 2060 show that cancer will overtake ischemic heart diseases (IHD) as the leading cause of death (18.9 million) immediately after 2030, surpassing non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. The clinical stage at the diagnosis is the main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential as the initial stages of cancer show reduced mortality compared to the advanced stages. Sophisticated approaches to proper histological classification and NSCLC management have improved clinical efficiency. Although immune checkpoint inhibitors (ICIs) and targeted molecular therapies have refined the therapeutic management of late-stage NSCLC, the specificity and sensitivity of cancer biomarkers should be improved by focusing on prospective studies, followed by their use as therapeutic tools. The liquid biopsy candidates such as circulating tumor cells (CTCs), circulating cell-free tumor DNA (cfDNA), tumor educated platelets (TEP), and extracellular vesicles (EVs) possess cancer-derived biomolecules and aid in tracing: driver mutations leading to cancer, acquired resistance caused by various generations of therapeutic agents, refractory disease, prognosis, and surveillance. Chongqing Medical University 2022-08-23 /pmc/articles/PMC10308181/ /pubmed/37396553 http://dx.doi.org/10.1016/j.gendis.2022.07.023 Text en © 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Padinharayil, Hafiza Varghese, Jinsu John, Mithun Chacko Rajanikant, Golgodu Krishnamurthy Wilson, Cornelia M. Al-Yozbaki, Minnatallah Renu, Kaviyarasi Dewanjee, Saikat Sanyal, Rupa Dey, Abhijit Mukherjee, Anirban Goutam Wanjari, Uddesh Ramesh Gopalakrishnan, Abilash Valsala George, Alex Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title_full | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title_fullStr | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title_full_unstemmed | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title_short | Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics |
title_sort | non-small cell lung carcinoma (nsclc): implications on molecular pathology and advances in early diagnostics and therapeutics |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308181/ https://www.ncbi.nlm.nih.gov/pubmed/37396553 http://dx.doi.org/10.1016/j.gendis.2022.07.023 |
work_keys_str_mv | AT padinharayilhafiza nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT varghesejinsu nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT johnmithunchacko nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT rajanikantgolgodukrishnamurthy nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT wilsoncorneliam nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT alyozbakiminnatallah nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT renukaviyarasi nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT dewanjeesaikat nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT sanyalrupa nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT deyabhijit nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT mukherjeeanirbangoutam nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT wanjariuddeshramesh nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT gopalakrishnanabilashvalsala nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics AT georgealex nonsmallcelllungcarcinomansclcimplicationsonmolecularpathologyandadvancesinearlydiagnosticsandtherapeutics |